Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

被引：0
|
作者：
Shannon Allen Ferrante
Jagpreet Chhatwal
Clifford A Brass
Antoine C El Khoury
Fred Poordad
Jean-Pierre Bronowicki
Elamin H Elbasha
机构：
[1] Merck Sharp & Dohme Corp.,Department of Health Policy and Management
[2] University of Pittsburgh Graduate School of Public Health,Department of Industrial Engineering
[3] University of Pittsburgh,Hepatology and Liver Transplantation
[4] Novartis,INSERM 954, Centre Hospitalier Universitaire de Nancy
[5] Cedars-Sinai Medical Center,undefined
[6] Université de Lorraine,undefined
来源：
BMC Infectious Diseases | / 13卷
关键词：
Cost-effectiveness; Economic evaluation; Hepatitis c virus; Boceprevir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study
    Ferrante, Shannon Allen
    Chhatwal, Jagpreet
    Brass, Clifford A.
    El Khoury, Antoine C.
    Poordad, Fred
    Bronowicki, Jean-Pierre
    Elbasha, Elamin H.
    [J]. BMC INFECTIOUS DISEASES, 2013, 13
  • [2] Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Enea, Marco
    Bruno, Raffaele
    Bronte, Fabrizio
    Capursi, Vincenza
    Cicchetti, Americo
    Colombo, Giorgio L.
    Di Marco, Vito
    Gasbarrini, Antonio
    Craxi, Antonio
    [J]. HEPATOLOGY, 2012, 56 (03) : 850 - 860
  • [3] COST-EFFECTIVENESS OF BOCEPREVIR BASED REGIMENS IN PREVIOUSLY UNTREATED ADULT SUBJECTS WITH CHRONIC HEPATITIS C GENOTYPE 1
    Ferrante, Shannon A.
    Chhatwal, Jagpreet
    Elbasha, Elamin
    Dasbach, Erik J.
    El Khoury, Antoine
    Poordad, F. Fred
    Bronowicki, Jean-Pierre
    Brass, Clifford A.
    [J]. HEPATOLOGY, 2011, 54 : 795A - 796A
  • [4] Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States
    Chhatwal, Jagpreet
    Ferrante, Shannon A.
    Brass, Cliff
    El Khoury, Antoine C.
    Burroughs, Margaret
    Bacon, Bruce
    Esteban-Mur, Rafael
    Elbasha, Elamin H.
    [J]. VALUE IN HEALTH, 2013, 16 (06) : 973 - 986
  • [5] Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Cabibbo, Giuseppe
    Ruggeri, Matteo
    Enea, Marco
    Bruno, Raffaele
    Capursi, Vincenza
    Gasbarrini, Antonio
    Alberti, Alfredo
    Craxi, Antonio
    [J]. JOURNAL OF HEPATOLOGY, 2013, 59 (04) : 658 - 666
  • [6] Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
    Petta, Salvatore
    Cabibbo, Giuseppe
    Enea, Marco
    Macaluso, Fabio Salvatore
    Plaia, Antonella
    Bruno, Raffaele
    Gasbarrini, Antonio
    Bruno, Savino
    Craxi, Antonio
    Camma, Calogero
    [J]. DIGESTIVE AND LIVER DISEASE, 2014, 46 (10) : 936 - 942
  • [7] Cost-Effectiveness Modeling Study of boceprevir for the treatment of patients with genotype 1 chronic hepatitis C virus infection in Hong Kong
    Ferrante, Shannon A.
    Yuen, Man-Fung
    Wong, Vincent W.
    Loo, Ching-Kong
    Chhatwal, Jagpreet
    Elbasha, Elamin
    [J]. HEPATOLOGY, 2013, 58 : 1136A - 1136A
  • [8] COST-EFFECTIVENESS OF BOCEPREVIR IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 IN SWEDEN
    Chhatwal, J.
    Lundberg, J.
    Ferrante, S.
    El Khourhy, A. C.
    Oksanen, A.
    Elbasha, E. H.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 : S386 - S387
  • [9] COST-EFFECTIVENESS OF BOCEPREVIR THERAPY IN ADULT PATIENTS WITH CHRONIC HEPATITIS C (HCV) GENOTYPE 1
    Mernagh, P.
    Feng, J.
    Del Cuore, M.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A94 - A94
  • [10] Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal
    Elbasha E.H.
    Chhatwal J.
    Ferrante S.A.
    El Khoury A.C.
    Laires P.A.
    [J]. Applied Health Economics and Health Policy, 2013, 11 (1) : 65 - 78
12345